文献速递毛发、甲与色素性疾病

非那雄胺使用者的自杀倾向与心理不良事件调查

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
PubMed 文献 · JAMA Dermatol · 2021-01-01

该药物警戒病例-非病例研究基于WHO VigiBase数据库,采用报告比值比(ROR)检测非那雄胺相关自杀倾向与心理不良事件的信号,发现自杀倾向ROR为1.63、心理不良事件ROR为4.33,且信号主要集中在45岁以下脱发患者,2012年后报告显著增加。

要点

  • 非那雄胺相关自杀倾向ROR 1.63(95%CI 1.47-1.81),心理不良事件ROR 4.33(95%CI 4.17-4.49)。
  • 45岁以下及脱发适应证患者自杀倾向信号显著,BPH老年患者未检出。
  • 2012年后相关不良事件报告显著增加(ROR 2.13,95%CI 1.91-2.39)。

核心结论

  • 非那雄胺使用与自杀倾向及心理不良事件存在显著报告比值比信号,主要见于45岁以下因脱发用药者。
  • 敏感性分析提示这些信号可能源于刺激报告和/或年轻患者对非那雄胺不良反应更易感。

研究设计与样本

  • 药物警戒病例-非病例研究,采用不成比例分析(disproportionality analysis)。
  • 数据来自WHO全球个体病例安全性报告数据库VigiBase,数据获取于2019年6月,分析于2020年1月25日至2月28日。
  • VigiBase含非那雄胺使用者356份自杀倾向报告和2926份心理不良事件报告,共3282份目标不良事件。
  • 报告者中男性3206例(98.9%);有年龄数据的868例中615例(70.9%)为18-44岁。

主要发现

  • 非那雄胺的自杀倾向ROR为1.63(95%CI 1.47-1.81),心理不良事件ROR为4.33(95%CI 4.17-4.49)。
  • 敏感性分析中,年轻患者自杀倾向ROR为3.47(95%CI 2.90-4.15),脱发适应证患者ROR为2.06(95%CI 1.81-2.34)。
  • 老年BPH患者中未检出上述自杀倾向信号。
  • 2012年后这些不良事件的报告显著增加,ROR为2.13(95%CI 1.91-2.39)。

关键数值与推荐

  • 自杀倾向:ROR 1.63(95%CI 1.47-1.81)。
  • 心理不良事件:ROR 4.33(95%CI 4.17-4.49)。
  • 年轻患者自杀倾向:ROR 3.47(95%CI 2.90-4.15);脱发适应证:ROR 2.06(95%CI 1.81-2.34)。
  • 2012年后报告增加:ROR 2.13(95%CI 1.91-2.39)。

临床怎么用

  • 对因脱发使用非那雄胺的年轻男性,应关注自杀倾向及抑郁、焦虑等心理不良事件。
  • 处方非那雄胺前及用药期间可评估心理状态,尤其45岁以下脱发患者。
  • 对BPH老年患者,现有信号未显示自杀倾向风险升高,但仍需个体化评估。

局限性

  • VigiBase为自发报告数据库,存在报告偏倚和刺激报告可能。
  • ROR为不成比例分析的替代关联指标,不能证明因果关系。
  • 部分报告缺少年龄等数据(有年龄数据者仅868例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is ongoing controversy about the adverse events of finasteride, a drug used in the management of alopecia and benign prostatic hyperplasia (BPH). In 2012, reports started emerging on men who had used finasteride and either attempted or completed suicide. OBJECTIVE: To investigate the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with finasteride use. DESIGN, SETTING, AND PARTICIPANTS: This pharmacovigilance case-noncase study used disproportionality analysis (case-noncase design) to detect signals of adverse reaction of interest reported with finasteride in VigiBase, the World Health Organization's global database of individual case safety reports. To explore the strength of association, the reporting odds ratio (ROR), a surrogate measure of association used in disproportionality analysis, was used. Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (≤45 and >45 years); comparing finasteride signals with those of drugs with different mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochloride for BPH); comparing finasteride with a drug with a similar mechanism of action and adverse event profile (dutasteride); and comparing reports of suicidality before and after 2012. Data were obtained in June 2019 and analyzed from January 25 to February 28, 2020. EXPOSURES: Reported finasteride use. MAIN OUTCOMES AND MEASURES: Suicidality and psychological adverse events. RESULTS: VigiBase contained 356 reports of suicidality and 2926 reports of psychological adverse events (total of 3282 adverse events of interest) in finasteride users (3206 male [98.9%]; 615 of 868 [70.9%] with data available aged 18-44 years). A significant disproportionality signal for suicidality (ROR, 1.63; 95% CI, 1.47-1.81) and psychological adverse events (ROR, 4.33; 95% CI, 4.17-4.49) in finasteride was identified. In sensitivity analyses, younger patients (ROR, 3.47; 95% CI, 2.90-4.15) and those with alopecia (ROR, 2.06; 95% CI, 1.81-2.34) had significant disproportionality signals for increased suicidality; such signals were not detected in older patients with BPH. Sensitivity analyses also showed that the reports of these adverse events significantly increased after 2012 (ROR, 2.13; 95% CI, 1.91-2.39). CONCLUSIONS AND RELEVANCE: In this pharmacovigilance case-noncase study, significant RORs of suicidality and psychological adverse events were associated with finasteride use in patients younger than 45 years who used finasteride for alopecia. The sensitivity analyses suggest that these disproportional signals of adverse events may be due to stimulated reporting and/or younger patients being more vulnerable to finasteride's adverse effects.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nguyen DD, Marchese M, Cone EB, et al. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatol. 2021. PMID: 33175100. doi:10.1001/jamadermatol.2020.3385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。